Marc Feldmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7564229/publications.pdf

Version: 2024-02-01

275 papers	37,988 citations	3515 90 h-index	3021 188 g-index
282 all docs	282 docs citations	282 times ranked	33272 citing authors

#	Article	IF	Citations
1	Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2000, 343, 1594-1602.	13.9	2,910
2	ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS. Annual Review of Immunology, 1996, 14, 397-440.	9.5	2,301
3	Infliximab (chimeric anti-tumour necrosis factor Î± monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet, The, 1999, 354, 1932-1939.	6.3	2,266
4	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	15.2	1,860
5	ANTI-TNFÎ± THERAPY OFRHEUMATOIDARTHRITIS: What Have We Learned?. Annual Review of Immunology, 2001, 19, 163-196.	9.5	1,207
6	IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature Immunology, 2011, 12, 231-238.	7.0	1,068
7	Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor Î±. Arthritis and Rheumatism, 1993, 36, 1681-1690.	6.7	1,000
8	Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology, 1988, 18, 1797-1802.	1.6	790
9	Role of interleukinâ€1Î² in postoperative cognitive dysfunction. Annals of Neurology, 2010, 68, 360-368.	2.8	623
10	Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology, 2002, 2, 364-371.	10.6	610
11	Tumor necrosis factor-Î± triggers a cytokine cascade yielding postoperative cognitive decline. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20518-20522.	3.3	600
12	TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine, 2003, 9, 1245-1250.	15.2	527
13	Macrophage heterogeneity in the context of rheumatoid arthritis. Nature Reviews Rheumatology, 2016, 12, 472-485.	3.5	493
14	Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet, The, 2020, 395, 1407-1409.	6.3	472
15	HLA class II induction in human islet cells by interferon-Î³ plus tumour necrosis factor or lymphotoxin. Nature, 1987, 326, 304-306.	13.7	463
16	Resolving postoperative neuroinflammation and cognitive decline. Annals of Neurology, 2011, 70, 986-995.	2.8	461
17	Anti-TNF therapy: past, present and future. International Immunology, 2015, 27, 55-62.	1.8	455
18	Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature, 1984, 312, 639-641.	13.7	434

#	Article	IF	Citations
19	Alarmins: awaiting a clinical response. Journal of Clinical Investigation, 2012, 122, 2711-2719.	3.9	408
20	Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunological Reviews, 2010, 233, 34-54.	2.8	407
21	Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor ? and interleukin-1 in rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 1258-1265.	6.7	360
22	Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-Î±, but not interleukin-10: Possible relevance to pathophysiology of rheumatoid arthritis. European Journal of Immunology, 1997, 27, 624-632.	1.6	352
23	Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: Involvement of phosphatidylinositol 3-kinase and nuclear factor ?B pathways in tumor necrosis factor ? production in rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 31-41.	6.7	330
24	TNF-Î± promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1585-1590.	3.3	319
25	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Reviews Rheumatology, 2009, 5, 578-582.	3.5	318
26	Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunological Reviews, 2008, 223, 7-19.	2.8	307
27	Canonical pathway of nuclear factor ÂB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5634-5639.	3.3	300
28	Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. European Journal of Immunology, 1990, 20, 2141-2144.	1.6	288
29	Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. European Journal of Immunology, 1996, 26, 1511-1518.	1.6	287
30	THE RELATIONSHIP BETWEEN ANTIGENIC STRUCTURE AND THE REQUIREMENT FOR THYMUS-DERIVED CELLS IN THE IMMUNE RESPONSE. Journal of Experimental Medicine, 1971, 134, 103-119.	4.2	275
31	CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1972, 136, 737-760.	4.2	257
32	Design of effective immunotherapy for human autoimmunity. Nature, 2005, 435, 612-619.	13.7	248
33	Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. European Journal of Immunology, 1994, 24, 2040-2048.	1.6	235
34	Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. European Journal of Immunology, 1996, 26, 2320-2328.	1.6	232
35	Monoclonal anti-TNFalpha Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease. Immunological Reviews, 1995, 144, 195-223.	2.8	225
36	Effective antigen presentation by dendritic cells is NF-ÎºB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. International Immunology, 2001, 13, 675-683.	1.8	215

#	Article	IF	Citations
37	VEGF expression in human macrophages is NF-Î²B-dependent: studies using adenoviruses expressing the endogenous NF-Î²B inhibitor IÎ²BÎ± and a kinase-defective form of the IÎ²B kinase 2. Journal of Cell Science, 2003, 116, 665-674.	1.2	207
38	Anti-Tumor Necrosis Factor-Î± Therapy of Rheumatoid Arthritis. Advances in Immunology, 1997, 64, 283-350.	1.1	204
39	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Science Immunology, 2020, 5, .	5.6	198
40	Distinct pathways of LPS-induced NF-Î²B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood, 2004, 103, 2229-2237.	0.6	186
41	Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. European Journal of Immunology, 1994, 24, 2699-2705.	1.6	184
42	Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-Î². European Journal of Immunology, 1991, 21, 1635-1639.	1.6	181
43	NF-κB as a Target for Modulating Inflammatory Responses. Current Pharmaceutical Design, 2012, 18, 5735-5745.	0.9	179
44	CELL-MEDIATED IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1972, 136, 331-343.	4.2	169
45	Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunological Reviews, 2004, 202, 250-265.	2.8	167
46	Historical review: Cytokines as therapeutics and targets of therapeutics. Trends in Pharmacological Sciences, 2004, 25, 201-209.	4.0	167
47	The Toll-Like Receptor Adaptor Proteins MyD88 and Mal/TIRAP Contribute to the Inflammatory and Destructive Processes in a Human Model of Rheumatoid Arthritis. American Journal of Pathology, 2007, 170, 518-525.	1.9	167
48	CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1972, 136, 722-736.	4.2	155
49	Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2372-2377.	3.3	154
50	CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1972, 136, 49-67.	4.2	153
51	Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine and Growth Factor Reviews, 2002, 13, 299-313.	3.2	153
52	Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis. Laboratory Investigation, 2000, 80, 1195-1205.	1.7	150
53	Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis. Circulation, 2009, 120, 2462-2469.	1.6	146
54	INDUCTION OF IMMUNITY AND TOLERANCE IN VITRO BY HAPTEN PROTEIN CONJUGATES. Journal of Experimental Medicine, 1972, 135, 735-753.	4.2	142

#	Article	IF	Citations
55	Cytokines in autoimmunity. Current Opinion in Immunology, 1996, 8, 872-877.	2.4	141
56	CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1972, 135, 1049-1058.	4.2	138
57	Developments in therapy with monoclonal antibodies and related proteins. Clinical Medicine, 2017, 17, 220-232.	0.8	137
58	T-cell lines producing antigen-specific suppressor factor. Nature, 1978, 274, 477-480.	13.7	135
59	A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis and Rheumatism, 2004, 50, 985-998.	6.7	134
60	ANTIBODY-MEDIATED SUPPRESSION OF THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1970, 131, 247-274.	4.2	131
61	Pathogenesis of arthritis: recent research progress. Nature Immunology, 2001, 2, 771-773.	7.0	130
62	A Novel Mechanism for TNF-Î± Regulation by p38 MAPK: Involvement of NF-ÎºB with Implications for Therapy in Rheumatoid Arthritis. Journal of Immunology, 2004, 173, 6928-6937.	0.4	129
63	Role of pro-inflammatory cytokines in rheumatoid arthritis. Seminars in Immunopathology, 1998, 20, 133-147.	4.0	127
64	Many cytokines are very useful therapeutic targets in disease. Journal of Clinical Investigation, 2008, 118, 3533-3536.	3.9	127
65	Therapeutic antibodies elicited by immunization against TNF-Î±. Nature Biotechnology, 1999, 17, 666-669.	9.4	126
66	IRF5 controls both acute and chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11001-11006.	3.3	125
67	Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction. Nature, 1984, 308, 72-74.	13.7	119
68	Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatology, The, 2020, 2, e653-e655.	2.2	119
69	Specific Collaboration between T and B Lymphocytes across a Cell Impermeable Membrane in vitro. Nature: New Biology, 1972, 237, 13-15.	4.5	117
70	Role of macrophages in in vitro induction of T-helper cells. Nature, 1975, 254, 352-354.	13.7	115
71	A human suppressor T cell clone which recognizes an autologous helper T cell clone. Nature, 1982, 300, 456-458.	13.7	115
72	ANTIBODY-MEDIATED SUPPRESSION OF THE IMMUNE RESPONSE IN VITRO. Journal of Experimental Medicine, 1970, 132, 31-43.	4.2	114

#	Article	IF	Citations
73	The role of macrophages in the generation of T helper cells. III. Influence of macrophage-derived factors in helper cell induction. European Journal of Immunology, 1975, 5, 759-766.	1.6	112
74	Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E928-37.	3.3	112
75	Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature, 1975, 258, 614-616.	13.7	111
76	Cell-mediated immune response in vitro. Cellular Immunology, 1972, 4, 39-50.	1.4	110
77	MONOSPECIFICITY OF BONE MARROW-DERIVED LYMPHOCYTES. Journal of Experimental Medicine, 1973, 137, 1024-1030.	4.2	110
78	Role of macrophages in the generation of T helper cells. IV. Nature of genetically related factor derived from macrophages incubated with soluble antigens. European Journal of Immunology, 1976, 6, 365-372.	1.6	110
79	Role of NFÎºB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. European Journal of Immunology, 2001, 31, 1883-1893.	1.6	107
80	The role of macrophages in the generation of T-helper cells. Cellular Immunology, 1975, 19, 356-367.	1.4	106
81	Evaluation of TNF-Î± and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-Î±/Anti-CD4 Therapy. Journal of Immunology, 2000, 165, 7240-7245.	0.4	105
82	Lowâ€dose <scp>TNF</scp> augments fracture healing in normal and osteoporotic bone by upâ€regulating the innate immune response. EMBO Molecular Medicine, 2015, 7, 547-561.	3.3	102
83	Different Therapeutic Outcomes in Experimental Allergic Encephalomyelitis Dependant Upon the Mode of Delivery of IL-10: A Comparison of the Effects of Protein, Adenoviral or Retroviral IL-10 Delivery into the Central Nervous System. Journal of Immunology, 2001, 166, 4124-4130.	0.4	101
84	Cytokines in autoimmunity. Current Opinion in Immunology, 1992, 4, 754-759.	2.4	99
85	Functional expression of HLA-DP genes transfected into mouse fibroblasts. Nature, 1985, 313, 61-64.	13.7	98
86	IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. Journal of Experimental Medicine, 2010, 207, 2081-2088.	4.2	97
87	Human T cells from autoimmune and normal individuals can produce tumor necrosis factor. European Journal of Immunology, 1987, 17, 1807-1814.	1.6	94
88	Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us?. Journal of Immunology, 2010, 185, 791-794.	0.4	93
89	Selective Tumor Necrosis Factor Receptor I Blockade Is Antiinflammatory and Reveals Immunoregulatory Role of Tumor Necrosis Factor Receptor II in Collagenâ€Induced Arthritis. Arthritis and Rheumatology, 2014, 66, 2728-2738.	2.9	93
90	Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-Î±-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 348-355.	1.3	92

#	Article	IF	Citations
91	Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13033-13038.	3.3	92
92	COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119.	3.3	92
93	Role of C3 in in vitro lymphocyte cooperation. Nature, 1974, 249, 159-161.	13.7	91
94	Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to G _{Alert}. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4463-E4472.	3.3	89
95	Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. European Journal of Immunology, 1999, 29, 2205-2212.	1.6	88
96	Suppressor cell inductionin vitro. II. Cellular requirements of suppressor cell induction. European Journal of Immunology, 1976, 6, 302-305.	1.6	87
97	Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. European Journal of Immunology, 1992, 22, 1907-1912.	1.6	87
98	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med, 2020, 1, 90-102.	2.2	87
99	Anti-TNF therapy: Where have we got to in 2005?. Journal of Autoimmunity, 2005, 25, 26-28.	3.0	85
100	Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures. Journal of Immunology, 2008, 181, 8002-8009.	0.4	85
101	B cell heterogeneityâ€"Difference in the size of B lymphocytes responding to T dependent and T independent antigens. Cellular Immunology, 1975, 18, 88-97.	1.4	84
102	Suppressor cell inductionin vitro. I. Kinetics of induction of antigen-specific suppressor cells. European Journal of Immunology, 1976, 6, 296-301.	1.6	84
103	Tolerance, Enhancement and the Regulation of Interactions Between T Cells, B Cells and Macrophages. Immunological Reviews, 1972, 13, 3-34.	2.8	83
104	Transforming growth factor Î² induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine, 1990, 2, 211-216.	1.4	80
105	Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-Î³ or IL-2 determines their function. International Immunology, 1995, 7, 1287-1294.	1.8	80
106	Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine, 2004, 28, 35-47.	1.4	80
107	Cell-mediated immune response in vitro. Cellular Immunology, 1972, 3, 405-420.	1.4	78
108	NF-ÎºB-Inducing Kinase Is Dispensable for Activation of NF-ÎºB in Inflammatory Settings but Essential for Lymphotoxin Î² Receptor Activation of NF-ÎºB in Primary Human Fibroblasts. Journal of Immunology, 2001, 167, 5895-5903.	0.4	78

#	Article	IF	Citations
109	Discovery of TNF-Î± as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine, 2002, 69, 12-18.	0.8	76
110	Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Current Opinion in Pharmacology, 2007, 7, 412-417.	1.7	75
111	Interleukin 7 is a growth factor for mature human T cells. European Journal of Immunology, 1990, 20, 425-428.	1.6	74
112	Direct triggering of B lymphocytes by insolubilized antigen. European Journal of Immunology, 1974, 4, 591-597.	1.6	73
113	In vitro studies on H-2-linked unresponsiveness to synthetic polypeptides. European Journal of Immunology, 1977, 7, 417-421.	1.6	73
114	TNF? Is an Effective Therapeutic Target for Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 1995, 766, 272-278.	1.8	73
115	Interleukin 4 induces interleukin 6 production by endothelial cells: Synergy with interferon-Î³. European Journal of Immunology, 1991, 21, 97-101.	1.6	72
116	The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2004, 18, 59-80.	1.4	72
117	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. Journal of Biological Chemistry, 2018, 293, 2422-2437.	1.6	72
118	Vascular endothelial growth factor signalling in endothelial cell survival: A role for NFÎºB. Biochemical and Biophysical Research Communications, 2006, 340, 984-994.	1.0	70
119	Inhibition of p38 Mitogen-Activated Protein Kinase Is Effective in the Treatment of Experimental Crescentic Glomerulonephritis and Suppresses Monocyte Chemoattractant Protein-1 but Not IL-1Î² or IL-6. Journal of the American Society of Nephrology: JASN, 2007, 18, 1167-1179.	3.0	70
120	TNFÎ±-induced macrophage chemokine secretion is more dependent on NF-ÎºB expression than lipopolysaccharides-induced macrophage chemokine secretion. European Journal of Immunology, 2002, 32, 2037.	1.6	68
121	Interleukin 7 (murine pre-B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta. European Journal of Immunology, 1989, 19, 783-786.	1.6	66
122	Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis. Molecular Medicine, 2007, 13, 40-58.	1.9	66
123	Rac mediates TNF-induced cytokine production via modulation of NF-ÎºB. Molecular Immunology, 2008, 45, 2446-2454.	1.0	66
124	Stimulation of the Î±7 Nicotinic Acetylcholine Receptor Protects against Neuroinflammation after Tibia Fracture and Endotoxemia in Mice. Molecular Medicine, 2014, 20, 667-675.	1.9	65
125	Induction of immunity and tolerancein vitro by hapten protein conjugates. II. Carrier independence of the response to dinitrophenylated polymerized flagellin. European Journal of Immunology, 1972, 2, 130-137.	1.6	64
126	IÎºB kinase 2 but not NF-ÎºBâ€“inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood, 2003, 101, 983-991.	0.6	64

#	Article	IF	Citations
127	CD44 Involvement in Experimental Collagen-Induced Arthritis (CIA). Journal of Autoimmunity, 1999, 13, 39-47.	3.0	62
128	Is There a Role for TNF-Î± in Anti-Neutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases. Journal of the American Society of Nephrology: JASN, 2006, 17, 1243-1252.	3.0	61
129	Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6056-6066.	3.3	61
130	TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21666-21672.	3.3	60
131	Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-Î³ and tumor necrosis factor-Î±. European Journal of Immunology, 1989, 19, 189-192.	1.6	58
132	Suppressor cell induction in vitro. European Journal of Immunology, 1977, 7, 310-314.	1.6	57
133	Nonsteroidal Anti-Inflammatory Drugs Increase TNF Production in Rheumatoid Synovial Membrane Cultures and Whole Blood. Journal of Immunology, 2010, 185, 3694-3701.	0.4	57
134	Tumour necrosis factor Î± as a therapeutic target for immune-mediated inflammatory diseases. Current Opinion in Biotechnology, 2004, 15, 557-563.	3.3	56
135	Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. Journal of Rheumatology, 2007, 34, 523-33.	1.0	56
136	Relationship Between Antigen and Antibody-Induced Suppression of Immunity. Immunological Reviews, 1972, 8, 76-103.	2.8	54
137	Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine, 1995, 7, 759-770.	1.4	54
138	Translating Molecular Insights in Autoimmunity into Effective Therapy. Annual Review of Immunology, 2009, 27, 1-27.	9.5	54
139	Induction of Immunity and Tolerance to the Dinitrophenyl Determinant in vitro. Nature: New Biology, 1971, 231, 21-23.	4.5	53
140	Cell interactions in the immune responsein vitro. I. Metabolic activities of T cells in a collaborative antibody response. European Journal of Immunology, 1972, 2, 213-224.	1.6	51
141	Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. Cytokine, 1990, 2, 60-67.	1.4	51
142	Evaluation of the role of cytokines in autoimmune disease: The importance of TNFÎ± in rheumatoid arthritis. Progress in Growth Factor Research, 1992, 4, 247-255.	1.7	50
143	Human macrophages inducedin vitroby macrophage colony-stimulating factor are deficient in IL-12 production. European Journal of Immunology, 1998, 28, 2498-2507.	1.6	50
144	Anti-TNF Therapy. Microbiology Spectrum, 2016, 4, .	1.2	50

#	Article	IF	Citations
145	Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?. Arthritis and Rheumatology, 2015, 67, 2283-2291.	2.9	49
146	Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. European Journal of Immunology, 1998, 28, 3904-3916.	1.6	48
147	Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16717-16722.	3.3	48
148	CD40 LIGATION INDUCES MACROPHAGE IL-10 AND TNF-Î± PRODUCTION: DIFFERENTIAL USE OF THE PI3K AND p42/44 MAPK-PATHWAYS. Cytokine, 2001, 16, 131-142.	1.4	47
149	Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis and Rheumatism, 2001, 44, 1215-1224.	6.7	47
150	CD200â€FC, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagenâ€induced arthritis. Arthritis and Rheumatism, 2008, 58, 1038-1043.	6.7	47
151	SIGIRR/TIRâ€8 is an inhibitor of tollâ€like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 2249-2261.	6.7	47
152	Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Research, 2012, 32, 1203-12.	0.5	47
153	T cell suppressionin vitro. II. Nature of specific suppressive factor. European Journal of Immunology, 1974, 4, 667-674.	1.6	46
154	Role of epitope density in the induction of immunity and tolerance with thymus-independent antigens. I. Studies with 2,4-dinitrophenyl conjugatesin vitro. European Journal of Immunology, 1975, 5, 537-541.	1.6	46
155	Preclinical target validation using patient-derived cells. Nature Reviews Drug Discovery, 2015, 14, 149-150.	21.5	46
156	A conversation with Marc Feldmann. Journal of Clinical Investigation, 2014, 124, 1-2.	3.9	46
157	Induction of Specific Helper Cells in vitro. Nature: New Biology, 1973, 245, 285-286.	4.5	45
158	Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. European Journal of Immunology, 1994, 24, 1879-1885.	1.6	45
159	Gene Therapy for Chronic Relapsing Experimental Allergic Encephalomyelitis Using Cells Expressing a Novel Soluble p75 Dimeric TNF Receptor. Journal of Immunology, 2000, 164, 2776-2781.	0.4	45
160	Monoclonal antibodies in immune and inflammatory diseases. Current Opinion in Biotechnology, 2002, 13, 615-620.	3.3	45
161	Blockade of NKG2D ameliorates disease in mice with collagenâ€induced arthritis: A potential pathogenic role in chronic inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 2617-2629.	6.7	45
162	Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20753-20763.	3.3	45

#	Article	IF	Citations
163	Mechanisms at the cellular level during induction of high zone tolerance in vitro. Cellular Immunology, 1972, 5, 130-136.	1.4	44
164	Serological analysis of antigen-specific helper factors specific for poly-L(Tyr,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (Glu)-poly-DLA 1979, 9, 501-506.	1.6	43
165	Murine IL-10 Gene Transfer Inhibits Established Collagen-Induced Arthritis and Reduces Adenovirus-Mediated Inflammatory Responses in Mouse Liver. Journal of Immunology, 2001, 166, 5970-5978.	0.4	41
166	The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. Annals of the Rheumatic Diseases, 2010, 69, 1519-1526.	0.5	41
167	HUMORAL AND CELL MEDIATED RESPONSES IN VITRO OF SPLEEN CELLS FROM MICE WITH THYMIC APLASIA (NUDE MICE). The Australian Journal of Experimental Biology and Medical Science, 1972, 50, 651-660.	0.7	39
168	The mechanism of antigenic competition. i. the macrophage as a site of a reversible block of t-b lymphocyte collaboration. European Journal of Immunology, 1973, 3, 711-717.	1.6	39
169	Long-term human T-helper lines producing specific helper factor reactive to influenza virus. Nature, 1981, 294, 166-168.	13.7	39
170	Interleukin-4 inhibits Ï‡ light chain expression and NFÏ‡B activation but not IÏ‡BÎ± degradation in 70Z/3 murine pre-B cells. European Journal of Immunology, 1995, 25, 2961-2966.	1.6	39
171	The Activity of Immunoregulatory T Cells Mediating Active Tolerance Is Potentiated in Nonobese Diabetic Mice by an IL-4-Based Retroviral Gene Therapy. Journal of Immunology, 2001, 166, 4973-4980.	0.4	39
172	Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis and Rheumatism, 2003, 48, 839-845.	6.7	39
173	Reduction of cPLA_{2Î±} overexpression: An efficient antiâ€inflammatory therapy for collagenâ€induced arthritis. European Journal of Immunology, 2008, 38, 2905-2915.	1.6	39
174	Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. EBioMedicine, 2018, 33, 282-288.	2.7	39
175	T cell suppressionin vitro. I. Role in regulation of antibody responses. European Journal of Immunology, 1974, 4, 660-666.	1.6	38
176	Antigen-specific T cell unresponsiveness in cloned helper T cells mediated via the CD2 or CD3/Ti receptor pathways. European Journal of Immunology, 1987, 17, 1641-1644.	1.6	38
177	Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine, 1993, 5, 205-212.	1.4	38
178	Selective Use of TRAM in Lipopolysaccharide (LPS) and Lipoteichoic Acid (LTA) Induced NF-ÎºB Activation and Cytokine Production in Primary Human Cells: TRAM Is an Adaptor for LPS and LTA Signaling. Journal of Immunology, 2007, 178, 2148-2154.	0.4	38
179	Anti- TNFÎ± Therapy of Rheumatoid Arthritis: What Can We Learn about Chronic Disease?. Novartis Foundation Symposium, 2008, , 53-73.	1.2	38
180	RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages. Cytokine, 2013, 61, 736-740.	1.4	38

#	Article	IF	Citations
181	INDUCTION OF IMMUNITY AND TOLERANCE IN VITRO BY HAPTEN PROTEIN CONJUGATES. Journal of Experimental Medicine, 1972, 136, 532-545.	4.2	37
182	Collagen VI as a driver and disease biomarker in human fibrosis. FEBS Journal, 2022, 289, 3603-3629.	2.2	37
183	T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. Journal of Leukocyte Biology, 2002, 71, 659-68.	1.5	37
184	OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2289-2294.	3.3	36
185	Balance between activating <scp>NKG</scp>2D, <scp>DNAM</scp>â€1, <scp>NK</scp>p44 and <scp>NK</scp>p46 and inhibitory <scp>CD</scp>94/<scp>NKG</scp>2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology, 2014, 142, 581-593.	2.0	36
186	Contrasting effects of interferon Î³ and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor Î±. Cytokine, 1992, 4, 470-478.	1.4	35
187	Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 206-219.	1.2	35
188	Cloning, expression and cross-linking analysis of the murine p55 tumor necrosis factor receptor. European Journal of Immunology, 1991, 21, 1649-1656.	1.6	34
189	Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Current Opinion in Immunology, 2004, 16, 780-786.	2.4	34
190	Immune response (Ir) genes expressed at macrophageâ€“B lymphocyte interactions. Nature, 1978, 273, 664-666.	13.7	33
191	Interleukin-7 activates human naive CD4+ cells and primes for interleukin-4 production. European Journal of Immunology, 1997, 27, 633-640.	1.6	33
192	Lack of requirement for cell cooperation in the antibody response to DNP conjugated to levan. Cellular Immunology, 1975, 16, 106-114.	1.4	32
193	MECHANISMS OF B-CELL TOLERANCE. British Medical Bulletin, 1976, 32, 141-146.	2.7	31
194	Selective Blockade of Tumor Necrosis Factor Receptor I Inhibits Proinflammatory Cytokine and Chemokine Production in Human Rheumatoid Arthritis Synovial Membrane Cell Cultures. Arthritis and Rheumatism, 2013, 65, 2262-2273.	6.7	31
195	Tâ€“T interaction in the generation of helper cells in vitro. Nature, 1975, 256, 741-743.	13.7	30
196	Immunological intervention reveals reciprocal roles for tumor necrosis factor-? and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Seminars in Immunopathology, 1994, 16, 327-36.	4.0	29
197	Alveolar Macrophages and T Cells from Sarcoid, but Not Normal Lung, Are Permissive to Adenovirus Infection and Allow Analysis of NF- Îº Bâ€“Dependent Signaling Pathways. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 141-149.	1.4	29
198	TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-ÎºB pathways and signals TRAF2 protein degradation in macrophages. Cellular Signalling, 2014, 26, 683-690.	1.7	29

#	Article	IF	Citations
199	Tolerance induction to a hapten protein conjugatein vivo: Are suppressor T cells involved. European Journal of Immunology, 1974, 4, 768-771.	1.6	28
200	Two-gene control of T-helper cell induction. Nature, 1976, 263, 601-604.	13.7	28
201	Inhibition of T cell proliferation by antibodies to synthetic peptides. European Journal of Immunology, 1984, 14, 153-157.	1.6	28
202	C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis. Nature Communications, 2022, 13, 215.	5.8	28
203	Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 MRNA. Biochemical and Biophysical Research Communications, 1988, 153, 1144-1151.	1.0	27
204	What Is the Mechanism of Action of Anti-Tumour Necrosis Factor-Î± Antibody in Rheumatoid Arthritis?. International Archives of Allergy and Immunology, 1996, 111, 362-365.	0.9	27
205	Dynamic Aspects of Antigen Binding to B Cells in Immune Induction. Nature: New Biology, 1972, 237, 3-5.	4.5	26
206	Post-transcriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1. Biochemical and Biophysical Research Communications, 1988, 156, 830-839.	1.0	25
207	Enrichment of antigen-specific helper and suppressor T cells. Nature, 1976, 260, 324-327.	13.7	24
208	TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine, 1994, 6, 616-623.	1.4	23
209	Cellular census of human fibrosis defines functionally distinct stromal cell types and states. Nature Communications, 2020, 11, 2768.	5.8	23
210	Macrophage-Lymphocyte Interactions in Immune Induction. International Review of Cytology, 1979, 60, 149-178.	6.2	22
211	Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-Î³) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes. Cytokine, 1992, 4, 287-297.	1.4	22
212	ROUTE OF MONOCYTE DIFFERENTIATION DETERMINES THEIR CYTOKINE PRODUCTION PROFILE: CD40 LIGATION INDUCES INTERLEUKIN 10 EXPRESSION. Cytokine, 2000, 12, 1496-1505.	1.4	22
213	Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis. Science Advances, 2019, 5, eaay0370.	4.7	22
214	EXPRESSION OF AN EFFICIENT SMALL MOLECULAR WEIGHT TUMOUR NECROSIS FACTOR/LYMPHOTOXIN ANTAGONIST. Cytokine, 1996, 8, 365-370.	1.4	21
215	The role of receptors for tumour necrosis factor-Î± in the induction of human polymorphonuclear neutrophil chemiluminescence. Immunology Letters, 1996, 53, 45-50.	1.1	21
216	An influenza virus matrix protein-specific human T cell line with helper activity forin vitro anti-hemagglutinin antibody production. European Journal of Immunology, 1982, 12, 844-849.	1.6	20

#	Article	IF	Citations
217	Mechanism of antigenic competition. Cellular Immunology, 1974, 14, 255-269.	1.4	19
218	Role of Antigen Structure in the Discrimination between Tolerance and Immunity by B Cells. Immunological Reviews, 1975, 23, 78-97.	2.8	19
219	Interleukin 1 (IL-1) and tumour necrosis factor synergise in the induction of IL-1 synthesis by human vascular endothelial cells. Immunology Letters, 1988, 19, 169-173.	1.1	18
220	RelB/p50 regulates CCL19 production, but fails to promote human DC maturation. European Journal of Immunology, 2009, 39, 2215-2223.	1.6	16
221	Cellular Basis of Antibody Production. Quarterly Review of Biology, 1972, 47, 269-302.	0.0	15
222	Are the Ir genes expressed by macrophages?. Nature, 1977, 267, 105-105.	13.7	15
223	Nature of macrophage-T cell interaction in secondary helper cell generationin vitro Genetic restriction of macrophage-T cell interaction, which determines T-B genetic restriction. European Journal of Immunology, 1981, 11, 377-381.	1.6	15
224	Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. Frontiers in Immunology, 2021, 12, 626255.	2.2	15
225	Role of epitope density in the induction of tolerance and immunity with thymus-independent antigens. III. Interaction of epitope density and receptor avidity. European Journal of Immunology, 1976, 6, 646-650.	1.6	14
226	Host-targeting oral antiviral drugs to prevent pandemics. Lancet, The, 2022, 399, 1381-1382.	6.3	14
227	The effects of tumor necrosis factor (TNF) derivatives on TNF receptors. Cytokine, 1993, 5, 125-132.	1.4	13
228	Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. FEBS Journal, 1994, 223, 831-840.	0.2	13
229	Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. Journal of Immunology, 2018, 201, 1727-1734.	0.4	13
230	Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytrenâ€™s disease, with an embedded dose response study.. Wellcome Open Research, 2017, 2, 37.	0.9	13
231	A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: Importance in human fibrotic disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120336119.	3.3	13
232	Cannabinoids in Models of Chronic Inflammatory Conditions. Phytochemistry Reviews, 2005, 4, 11-18.	3.1	12
233	Novel biomarkers of a peripheral blood interferon signature associated with drug-naÃ¯ve early arthritis patients distinguish persistent from self-limiting disease course. Scientific Reports, 2020, 10, 8830.	1.6	12
234	A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma. European Journal of Immunology, 1987, 17, 1441-1446.	1.6	11

#	Article	IF	Citations
235	Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?. Novartis Foundation Symposium, 2004, 256, 53-69; discussion 69-73, 106-11, 266-9.	1.2	11
236	Reversible Blocking Effect of Anti-mouse Immunoglobulin Serum on the Induction of Immunity and Tolerance in vitro. Nature: New Biology, 1971, 231, 183-184.	4.5	10
237	Relative Affinity and Avidity of the Antigen-binding Receptors of T and B Rosette-forming Cells. Nature: New Biology, 1973, 245, 177-180.	4.5	10
238	A monoclonal antibody against antigen-specific helper factor augments T-cell help. Nature, 1983, 301, 160-163.	13.7	10
239	Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules, 2021, 26, 5601.	1.7	10
240	Direct evaluation of antigen binding to human T lymphocyte clones: involvement of major histocompatibility complex products in antigen binding. European Journal of Immunology, 1984, 14, 1101-1105.	1.6	8
241	Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the neu proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu. Cancer Immunology, Immunotherapy, 1996, 42, 179-184.	2.0	8
242	A new JCI conflict-of-interest policy. Journal of Clinical Investigation, 2007, 117, 506-508.	3.9	8
243	COMPARISON OF ANTIGEN-SPECIFIC I-REGION-ASSOCIATED CELL INTERACTION FACTORS. Annals of the New York Academy of Sciences, 1979, 332, 591-604.	1.8	7
244	Antigen specific T cell factors. Molecular and Cellular Biochemistry, 1980, 30, 177-93.	1.4	7
245	New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. Current Opinion in Pharmacology, 2004, 4, 368-371.	1.7	7
246	The Detection of Autoantibody-Forming Cells. International Archives of Allergy and Immunology, 1972, 42, 627-640.	0.9	6
247	Complementation ofH-2-linkedIr genes: Use of helper factor to analyze responses to GLPhe. Immunogenetics, 1978, 6, 471-481.	1.2	6
248	HUMAN T-CELL RESPONSES IN VITRO: CELL INTERACTIONS AND FACTORS. Annals of the New York Academy of Sciences, 1979, 332, 503-515.	1.8	6
249	Immunology: Lymphokines and interleukins emerge from the primeval soup. Nature, 1985, 313, 351-352.	13.7	6
250	Specific Interactions between a Human CD4+ Clone and Autologous CD4+ Bifunctional Immunoregulatory Clones. Immunological Reviews, 1990, 116, 63-83.	2.8	6
251	Interactions between autologous T cell clones. Cellular Immunology, 1990, 128, 490-502.	1.4	6
252	Effect of soluble P55 tumourâ€•necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions. British Journal of Pharmacology, 1996, 117, 471-478.	2.7	6

#	Article	IF	Citations
253	The pitfalls in the development of biologic therapy. Nature Clinical Practice Rheumatology, 2007, 3, 1-1.	3.2	6
254	Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states. Biology Open, 2020, 9, .	0.6	6
255	Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets. Drug Discovery Today Disease Mechanisms, 2004, 1, 289-295.	0.8	5
256	Design and Optimisation of Bioactive Cyclic Peptides: Generation of a Down-Regulator of TNF Secretion. Molecules, 2014, 19, 21529-21540.	1.7	5
257	Thymus-independent IgM and IgG Responses in Mice to Flagellar Antigens. International Archives of Allergy and Immunology, 1974, 46, 600-611.	0.9	4
258	Anti-TNF Therapy. , 2017, , 637-648.		4
259	ROLE OF T-CELL IMMUNOGLOBULIN IN CELL COOPERATION, T-CELL SUPPRESSION, AND ANTIGENIC COMPETITION. Annals of the New York Academy of Sciences, 1975, 249, 424-437.	1.8	3
260	Biochemical events initiated by exposure of human T lymphocyte clones to immunogenic and tolerogenic concentrations of antigen. European Journal of Immunology, 1985, 15, 302-305.	1.6	3
261	The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer. Molecular Immunology, 1999, 36, 125-134.	1.0	3
262	Gene therapy for rheumatoid arthritis?. Journal of Clinical Investigation, 2001, 107, 1353-1353.	3.9	3
263	Le TNF-Î± comme cible thÃ©rapeutique dans la polyarthrite rhumatoÃ¯deÂ: dÃ©couverte, Ã©tudes prÃ©cliniques et cliniques. Revue Du Rhumatisme (Edition Francaise), 2002, 69, 12-19.	0.0	2
264	Cellular Interactions in Antibody Production. Clinics in Rheumatic Diseases, 1978, 4, 481-498.	1.2	2
265	B cell stimulatory factor 2(BSF2/IL-6) and rheumatoid arthritis.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1987, 63, 281-283.	1.6	1
266	Antilipid a monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. Cytokine, 1993, 5, 570-577.	1.4	1
267	Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line. International Immunology, 1995, 7, 1057-1063.	1.8	1
268	Increased Urinary Neopterin Excretion in Vaccinated Adults. Pteridines, 1996, 7, 82-86.	0.5	1
269	Targeting intracellular signaling: a novel approach to vaccination. Expert Review of Vaccines, 2007, 6, 971-980.	2.0	1
270	Cancer immunotherapy in routine costâ€effective cancer care?. EMBO Molecular Medicine, 2018, 10, .	3.3	1

#	Article	IF	Citations
271	Biological insights from clinical trials with anti-TNF therapy. Seminars in Immunopathology, 1998, 20, 211-228.	4.0	1
272	CYTOKINES IN RHEUMATOID ARTHRITIS : IS TNFalpha OF HAAJOR IMPORTANCE?. Clinical and Experimental Allergy, 1993, 23, 35-35.	1.4	0
273	POTENTIATION OF TNF-Î± TOXICITY BY CONJUGATION WITH RICIN A-CHAIN. Cytokine, 1998, 10, 931-939.	1.4	0
274	Reply. Arthritis and Rheumatology, 2014, 66, 1962-1963.	2.9	0
275	Induction of autoimmunity: is there a role for infectious agents?. Memorias Do Instituto Oswaldo Cruz, 1987, 82, 274-286.	0.8	0